Endothelial cell mTOR complex-2 regulates sprouting angiogenesis

PLoS ONE

Volumn 10, Issue 8, 2015, Pages

  Farhan, Maikel A ^a   Carmine Simmen, Katia ^a   Lewis, John D ^a   Moore, Ronald B ^a   Murray, Allan G ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN; F ACTIN; FOCAL ADHESION KINASE; G ACTIN; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; RNA; S6 KINASE; TRANSCRIPTION FACTOR FKHR; VASCULOTROPIN; 2 (4 AMINO 1 ISOPROPYL 1H PYRAZOLO[3,4 D]PYRIMIDIN 3 YL) 1H INDOL 5 OL; 5 [2 (2,6 DIMETHYLMORPHOLINO) 4 MORPHOLINOPYRIDO[2,3 D]PYRIMIDIN 7 YL] 2 METHOXYBENZENEMETHANOL; AKT1 PROTEIN, HUMAN; FOCAL ADHESION KINASE 1; INDOLE DERIVATIVE; MECHANISTIC TARGET OF RAPAMYCIN COMPLEX 1; MORPHOLINE DERIVATIVE; MTOR PROTEIN, HUMAN; MULTIPROTEIN COMPLEX; PROTEIN KINASE B; PTK2 PROTEIN, HUMAN; PURINE DERIVATIVE; PYRIMIDINE DERIVATIVE; RAPAMYCIN; SMALL INTERFERING RNA; TARGET OF RAPAMYCIN KINASE; TOR COMPLEX 2; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ACTIN POLYMERIZATION; ANGIOGENESIS; APOPTOSIS; ARTICLE; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE MICROSCOPY; KIDNEY CARCINOMA; NEOVASCULARIZATION (PATHOLOGY); RNA INTERFERENCE; SPROUTING; TUMOR GROWTH; WESTERN BLOTTING; ACTIN FILAMENT; ANTAGONISTS AND INHIBITORS; CELL ADHESION; CELL MOTION; CHEMISTRY; COCULTURE; CYTOLOGY; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE; UMBILICAL VEIN ENDOTHELIAL CELL;

ACTIN CYTOSKELETON; ACTINS; CARCINOMA, RENAL CELL; CELL ADHESION; CELL LINE, TUMOR; CELL MOVEMENT; COCULTURE TECHNIQUES; FOCAL ADHESION KINASE 1; GENE EXPRESSION REGULATION; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; INDOLES; MORPHOLINES; MULTIPROTEIN COMPLEXES; NEOVASCULARIZATION, PATHOLOGIC; PROTO-ONCOGENE PROTEINS C-AKT; PURINES; PYRIMIDINES; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; SIROLIMUS; TOR SERINE-THREONINE KINASES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84943154401     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0135245     Document Type: Article

References (49)

1. Kapoor A, Figlin RA. Targeted inhibition of mammalian target of rapamycin for the treatment of advanced renal cell carcinoma. Cancer. 2009;115:3618-3630. doi: 10.1002/cncr.24409 PMID: 19479976
2. Del Bufalo D, Ciuffreda L, Trisciuoglio D, Desideri M, Cognetti F, Zupi G, et al. Antiangiogenic potential of the mammalian target of rapamycin inhibitor temsirolimus. Cancer Res. 2006;66:5549-5554. PMID: 16740688
3. Guba M, Von Breitenbuch P, Steinbauer M, Koehl G, Flegel S, Hornung M, et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med. 2002;8:128-135. PMID: 11821896
4. Hutson TE, Bukowski RM, Cowey CL, Figlin R, Escudier B, Sternberg CN. Sequential use of targeted agents in the treatment of renal cell carcinoma. [Review]. Crit Rev Oncol Hematol. 2011;77:48-62. doi: 10.1016/j.critrevonc.2010.07.018 PMID: 20705477
5. Hutson TE, Escudier B, Esteban E, Bjarnason GA, Lim HY, Pittman KB, et al. Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2014;32:760-767. doi: 10.1200/JCO.2013.50.3961 PMID: 24297950
6. Takahara T, Maeda T. Evolutionarily conserved regulation of TOR signalling. J Biochem (Tokyo). 2013;154:1-10.
7. Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell. 2012;149:274-293. doi: 10.1016/j.cell.2012.03.017 PMID: 22500797
8. Ruan GX, Kazlauskas A. Axl is essential for VEGF-A-dependent activation of PI3K/Akt. EMBO J. 2012;31:1692-1703. doi: 10.1038/emboj.2012.21 PMID: 22327215
9. Xue Q, Nagy JA, Manseau EJ, Phung TL, Dvorak HF, Benjamin LE. Rapamycin inhibition of the Akt/mTOR pathway blocks select stages of VEGF-A164-driven angiogenesis, in part by blocking S6Kinase. Arterioscler Thromb Vasc Biol. 2009;29:1172-1178. doi: 10.1161/ATVBAHA.109.185918 PMID: 19443844
10. Benjamin D, Colombi M, Moroni C, Hall MN. Rapamycin passes the torch: a new generation of mTOR inhibitors. Nat Rev Drug Discov. 2011;10:868-880. doi: 10.1038/nrd3531 PMID: 22037041
11. Falcon BL, Barr S, Gokhale PC, Chou J, Fogarty J, Depeille P, et al. Reduced VEGF production, angiogenesis, and vascular regrowth contribute to the antitumor properties of dual mTORC1/mTORC2 inhibitors. Cancer Res. 2011;71:1573-1583. doi: 10.1158/0008-5472. CAN-10-3126 PMID: 21363918
12. Feldman ME, Apsel B, Uotila A, Loewith R, Knight ZA, Ruggero D, et al. Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol. 2009;7:e38. doi: 10.1371/journal.pbio.1000038 PMID: 19209957
13. Garcia-Martinez JM, Moran J, Clarke RG, Gray A, Cosulich SC, Chresta C, et al. Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR). Biochem J. 2009;421:29-42. doi: 10. 1042/BJ20090489 PMID: 19402821
14. Zhang QX, Nakhaei-Najad M, Haddad G, Murray AG. Endothelial PI3 kinase-á couples to VEGFR2, but is not required for eNOS activation. Am J Physiol. 2011;301:1242-1250.
15. Nakatsu MN, Hughes CC. An optimized three-dimensional in vitro model for the analysis of angiogenesis. Methods Enzymol. 2008;443:65-82. doi: 10.1016/S0076-6879 (08) 02004-1 PMID: 18772011
16. Zijlstra A, Lewis JD (2012) Visualization and quantification of de novo angiogenesis in ex ovo chicken embryos. In: Zudaire E, Cuttitta F, editors. The textbook of angiogenesis and lymphangiogenesis: Methods and applications. New York, NY: Springer. pp. 217-240.
17. Angers-Loustau A, C√t√© J-Fo, Charest A, Dowbenko D, Spencer S, Lasky LA, et al. Protein Tyrosine Phosphatase-PEST Regulates Focal Adhesion Disassembly, Migration, and Cytokinesis in Fibroblasts. The Journal of Cell Biology. 1999;144:1019-1031. PMID: 10085298
18. O'Reilly KE, Rojo F, She QB, Solit D, Mills GB, Smith D, et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. 2006;66:1500-1508. PMID: 16452206
19. Chandarlapaty S, Sawai A, Scaltriti M, Rodrik-Outmezguine V, Grbovic-Huezo O, Serra V, et al. AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. Cancer Cell. 2011;19:58-71. doi: 10.1016/j.ccr.2010.10.031 PMID: 21215704
20. Kim DH, Sarbassov DD, Ali SM, King JE, Latek RR, Erdjument-Bromage H, et al. mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell. 2002;110:163-175. PMID: 12150925
21. Sarbassov DD, Ali SM, Kim DH, Guertin DA, Latek RR, Erdjument-Bromage H, et al. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol. 2004;14:1296-1302. PMID: 15268862
22. Guertin DA, Stevens DM, Thoreen CC, Burds AA, Kalaany NY, Moffat J, et al. Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1. Dev Cell. 2006;11:859-871. PMID: 17141160
23. Jacinto E, Loewith R, Schmidt A, Lin S, Ruegg MA, Hall A, et al. Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol. 2004;6:1122-1128. PMID: 15467718
24. Wary KK, Kohler EE, Chatterjee I. Focal adhesion kinase regulation of neovascularization. Microvasc Res. 2012;83:64-70. doi: 10.1016/j.mvr.2011.05.002 PMID: 21616084
25. Eliceiri BP, Puente XS, Hood JD, Stupack DG, Schlaepfer DD, Huang XZ, et al. Src-mediated coupling of focal adhesion kinase to integrin alpha (v) beta5 in vascular endothelial growth factor signaling. J Cell Biol. 2002;157:149-160. PMID: 11927607
26. Lane HA, Wood JM, McSheehy PM, Allegrini PR, Boulay A, Brueggen J, et al. mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor. Clin Cancer Res. 2009;15:1612-1622. doi: 10.1158/1078-0432. CCR-08-2057 PMID: 19223496
27. Saito K, Matsumoto S, Yasui H, Devasahayam N, Subramanian S, Munasinghe JP, et al. Longitudinal imaging studies of tumor microenvironment in mice treated with the mTOR inhibitor rapamycin. PLoS ONE. 2012;7:e49456. doi: 10.1371/journal.pone.0049456 PMID: 23185335
28. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007;356:2271-2281. PMID: 17538086
29. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer. 2010;116:4256-4265. doi: 10.1002/cncr.25219 PMID: 20549832
30. Cacheux W, Boisserie T, Staudacher L, Vignaux O, Dousset B, Soubrane O, et al. Reversible tumor growth acceleration following bevacizumab interruption in metastatic colorectal cancer patients scheduled for surgery. Ann Oncol. 2008;19:1659-1661. doi: 10.1093/annonc/mdn540 PMID: 18684697
31. Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell. 2009;15:232-239. doi: 10.1016/j.ccr.2009.01.021 PMID: 19249681
32. Griffioen AW, Mans LA, De Graaf AM, Nowak-Sliwinska P, De Hoog CL, De Jong TA, et al. Rapid angiogenesis onset after discontinuation of sunitinib treatment of renal cell carcinoma patients. Clin Cancer Res. 2012;18:3961-3971. doi: 10.1158/1078-0432. CCR-12-0002 PMID: 22573349
33. Powles T, Kayani I, Sharpe K, Lim L, Peters J, Stewart G, et al. A prospective evaluation of VEGF-targeted treatment cessation in metastatic clear cell renal cancer. Ann Oncol. 2013;24:2098-2103. doi: 10.1093/annonc/mdt130 PMID: 23579815
34. Phung TL, Ziv K, Dabydeen D, Eyiah-Mensah G, Riveros M, Perruzzi C, et al. Pathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycin. Cancer Cell. 2006;10:159-170. PMID: 16904613
35. Kerbel RS. Tumor angiogenesis. [Review] [100 refs]. N Engl J Med. 2008;358:2039-2049. doi: 10. 1056/NEJMra0706596 PMID: 18463380
36. Chresta CM, Davies BR, Hickson I, Harding T, Cosulich S, Critchlow SE, et al. AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity. Cancer Res. 2010;70:288-298. doi: 10.1158/0008-5472. CAN-09-1751 PMID: 20028854
37. Gokmen-Polar Y, Liu Y, Toroni RA, Sanders KL, Mehta R, Badve S, et al. Investigational drug MLN0128, a novel TORC1/2 inhibitor, demonstrates potent oral antitumor activity in human breast cancer xenograft models. Breast Cancer Res Treat. 2012;136:673-682. doi: 10.1007/s10549-012-2298-8 PMID: 23085766
38. Giubellino A, Bullova P, Nolting S, Turkova H, Powers JF, Liu Q, et al. Combined inhibition of mTORC1 and mTORC2 signaling pathways is a promising therapeutic option in inhibiting pheochromocytoma tumor growth: in vitro and in vivo studies in female athymic nude mice. Endocrinology. 2013;154:646-655. doi: 10.1210/en. 2012-1854 PMID: 23307788
39. Zhang H, Berel D, Wang Y, Li P, Bhowmick NA, Figlin RA, et al. A comparison of Ku0063794, a dual mTORC1 and mTORC2 inhibitor, and temsirolimus in preclinical renal cell carcinoma models. PLoS ONE. 2013;8:e54918. doi: 10.1371/journal.pone.0054918 PMID: 23349989
40. Luchman HA, Stechishin OD, Nguyen SA, Lun XQ, Cairncross JG, Weiss S. Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival. Clin Cancer Res. 2014;20:5756-5767. doi: 10.1158/1078-0432. CCR-13-3389 PMID: 25316808
41. Carver BS, Chapinski C, Wongvipat J, Hieronymus H, Chen Y, Chandarlapaty S, et al. Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell. 2011;19:575-586. doi: 10.1016/j.ccr.2011.04.008 PMID: 21575859
42. Rodrik-Outmezguine-VS, Chandarlapaty S, Pagano NC, Poulikakos PI, Scaltriti M, Moskatel E, et al. mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling. Cancer Discov. 2011;1:248-259. doi: 10.1158/2159-8290. CD-11-0085 PMID: 22140653
43. Schaller MD, Hildebrand JD, Shannon JD, Fox JW, Vines RR, Parsons JT. Autophosphorylation of the focal adhesion kinase, pp125FAK, directs SH2-dependent binding of pp60src. Mol Cell Biol. 1994;14:1680-1688. PMID: 7509446
44. Schaller MD, Hildebrand JD, Parsons JT. Complex formation with focal adhesion kinase: A mechanism to regulate activity and subcellular localization of Src kinases. Mol Biol Cell. 1999;10:3489-3505. PMID: 10512882
45. Ilic D, Furuta Y, Kanazawa S, Takeda N, Sobue K, Nakatsuji N, et al. Reduced cell motility and enhanced focal adhesion contact formation in cells from FAK-deficient mice. Nature. 1995;377:539-544. PMID: 7566154
46. McDonald PC, Oloumi A, Mills J, Dobreva I, Maidan M, Gray V, et al. Rictor and integrin-linked kinase interact and regulate Akt phosphorylation and cancer cell survival. Cancer Res. 2008;68:1618-1624. doi: 10.1158/0008-5472. CAN-07-5869 PMID: 18339839
47. Masson-Gadais B, Houle F, Laferriere J, Huot J. Integrin alphavbeta3, requirement for VEGFR2-mediated activation of SAPK2/p38 and for Hsp90-dependent phosphorylation of focal adhesion kinase in endothelial cells activated by VEGF. Cell Stress Chaperones. 2003;8:37-52. PMID: 12820653
48. Le Boeuf F, Houle F, Huot J. Regulation of vascular endothelial growth factor receptor 2-mediated phosphorylation of focal adhesion kinase by heat shock protein 90 and Src kinase activities. J Biol Chem. 2004;279:39175-39185. PMID: 15247219
49. Duval M, Le Boeuf F, Huot J, Gratton JP. Src-mediated phosphorylation of Hsp90 in response to vascular endothelial growth factor (VEGF) is required for VEGF receptor-2 signaling to endothelial NO synthase. Mol Biol Cell. 2007;18:4659-4668. PMID: 17855507